Journal ArticleDOI
Serious infections in patients with inflammatory bowel disease receiving anti-tumor-necrosis-factor-alpha therapy: an Australian and New Zealand experience.
Ian C. Lawrance,Graham L. Radford-Smith,Graham L. Radford-Smith,Peter A. Bampton,Jane M. Andrews,Pok-Kern Tan,Anthony Croft,Richard B. Gearry,Timothy H. Florin +8 more
Reads0
Chats0
TLDR
The aim of this study was to examine the Australian/New Zealand experience of serious infections and TB in IBD patients receiving anti‐TNF‐α therapy from 1999–2009.Abstract:
Ian C Lawrance, Graham L Radford-Smith, Peter A Bampton, Jane M Andrews, Pok-Kern Tan, Anthony Croft, Richard B Gearry and Timothy H J Florinread more
Citations
More filters
Book ChapterDOI
Sepsis, the Liver and the Gut
TL;DR: The gastrointestinal tract has various functions including digestion, the production of hormones with local and systemic effects, a major role in immunological function, and acting as a barrier against antigens within its lumen.
Guías de recomendaciones de prevención de infecciones en pacientes que reciben modificadores de la respuesta biológica
Rosana Jordán,Alejandra Valledor +1 more
TL;DR: In el presente documento desarrollaremos los agentes mas importantes tales as: anti-TNF, anti-citoquinas, bloqueadores de la senal coestimulada, quimioprofilaxis and vacunacion necesaria ante cada agente in especial para evitar infecciones in this grupo de pacientes.
Journal ArticleDOI
Beneficial effects of Ajuga chamaepitys (L.) Schreber subsp. chia (Schreber) and its iridoids on the colitis model: Histopathological and biochemical evidence.
TL;DR: A. chia can be used in cell, tissue, or individual-specific treatments that will be developed in the future treatment of IBD, or as a complementary therapeutic agent that contributes to these treatments.
Journal ArticleDOI
Zweiter österreichischer Konsensus zur sicheren Anwendung von anti-TNF-α-Antikörpern bei chronisch-entzündlichen Darmerkrankungen
Wolfgang Miehsler,Clemens Dejaco,H. P. Gröchenig,H Fuchssteiner,Christoph Högenauer,Lili Kazemi-Shirazi,Harald Maier,A Mayer,Alexander R. Moschen,Walter Reinisch,Wolfgang Petritsch,R. Platzer,P Steiner,Herbert Tilg,Harald Vogelsang,Heimo H. Wenzl,Gottfried Novacek +16 more
TL;DR: Da der Konsensusbericht als praktischer Leitfaden fur die sichere Anwendung dieser Substanzen dienen soll, wurden die relevanten Aspekte in einer Checkliste zusammengefasst, die sich in zwei Teile „vor Therapie“ and „wahrend Therapies“ gliedert.
Journal ArticleDOI
Real-life burden of adverse reactions to biological therapy in inflammatory bowel disease: a single-centre prospective case series.
Tiziana Larussa,Antonio Basile,Caterina Palleria,Chiara Iannelli,Ada Vero,Lidia Giubilei,Caterina De Sarro,Evelina Suraci,Raffaella Marasco,Maria Imeneo,Emilio Russo,Ludovico Abenavoli,Giovambattista De Sarro,Francesco Luzza +13 more
TL;DR: In this paper, the authors evaluated the occurrence of spontaneous adverse drug reactions (ADRs) in inflammatory bowel disease (IBD) patients treated with biologics from a single centre in Southern Italy.
References
More filters
Journal ArticleDOI
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Stephen B. Hanauer,Brian G. Feagan,Gary R. Lichtenstein,Lloyd Mayer,Stefan Schreiber,Jean-Frederic Colombel,Daniel Rachmilewitz,Douglas C. Wolf,Allan Olson,Weihang Bao,Paul Rutgeerts +10 more
TL;DR: Patients with Crohn's disease who respond to an initial dose of infliximab are more likely to be in remission at weeks 30 and 54, to discontinue corticosteroids, and to maintain their response for a longer period of time, if inflIXimab treatment is maintained every 8 weeks.
Journal ArticleDOI
Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent
Joseph Keane,Sharon K. Gershon,Robert P. Wise,Elizabeth Mirabile-Levens,John Kasznica,William D. Schwieterman,Jeffrey Siegel,M. Miles Braun +7 more
TL;DR: Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis but there is no direct evidence of a protective role of TNF- α in patients with tuberculosis.
Journal ArticleDOI
Infliximab for induction and maintenance therapy for ulcerative colitis.
Paul Rutgeerts,William J. Sandborn,Brian G. Feagan,Walter Reinisch,Allan Olson,Jewel Johanns,Suzanne Travers,Daniel Rachmilewitz,Stephen B. Hanauer,Gary R. Lichtenstein,Willem J.S. de Villiers,Daniel H. Present,Bruce E. Sands,Jean-Frederic Colombel +13 more
TL;DR: Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Journal ArticleDOI
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Mark S. Silverberg,Jack Satsangi,Tariq Ahmad,Ian D. Arnott,Charles N. Bernstein,Steven R. Brant,Renzo Caprilli,Jean-Frederic Colombel,Christoph Gasche,Karel Geboes,Derek P. Jewell,Amir Karban,Edward V. Loftus,A. Salvador Peña,Robert H. Riddell,David B. Sachar,Stefan Schreiber,A. Hillary Steinhart,Stephan R. Targan,Severine Vermeire,Bryan F. Warren +20 more
TL;DR: The introduction of a widely acceptable clinical subclassification is strongly advocated, which would allow detailed correlations among serotype, genotype and clinical phenotype to be examined and confirmed in independent cohorts of patients and, thereby, provide a vital foundation for future work.
Journal ArticleDOI
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.
Jean-Frederic Colombel,William J. Sandborn,Paul Rutgeerts,Robert Enns,Stephen B. Hanauer,Remo Panaccione,Stefan Schreiber,Dan Byczkowski,Ju Li,J. D. Kent,Paul F. Pollack +10 more
TL;DR: Adalimumab was well-tolerated, with a safety profile consistent with previous experience with the drug, and was significantly more effective than placebo in maintaining remission in moderate to severe CD through 56 weeks.
Related Papers (5)
European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.
Jean-François Rahier,Fernando Magro,Candida Abreu,Alessandro Armuzzi,Shomron Ben-Horin,Yehuda Chowers,Mario Cottone,L. de Ridder,Glen A. Doherty,Robert Ehehalt,Maria Esteve,K.H. Katsanos,Charlie W. Lees,Eithne MacMahon,Tom G. Moreels,Walter Reinisch,Herbert Tilg,Lydjie Tremblay,Gigi Veereman-Wauters,N. Viget,Yazdan Yazdanpanah,Rami Eliakim,Jean-Frederic Colombel +22 more